Abbott Laboratories Statistics
Share Statistics
Abbott Laboratories has 1.73B shares outstanding. The number of shares has increased by -0.04% in one year.
| Shares Outstanding | 1.73B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.31% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.72B |
| Failed to Deliver (FTD) Shares | 12.93K |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 12.10M, so 0.7% of the outstanding shares have been sold short.
| Short Interest | 12.10M |
| Short % of Shares Out | 0.7% |
| Short % of Float | 0.7% |
| Short Ratio (days to cover) | 2.56 |
Valuation Ratios
The PE ratio is 33.35 and the forward PE ratio is 22.57. Abbott Laboratories's PEG ratio is 0.66.
| PE Ratio | 33.35 |
| Forward PE | 22.57 |
| PS Ratio | 4.76 |
| Forward PS | 4.1 |
| PB Ratio | 4.94 |
| P/FCF Ratio | 37.73 |
| PEG Ratio | 0.66 |
Enterprise Valuation
Abbott Laboratories has an Enterprise Value (EV) of 200.50B.
| EV / Earnings | 35.03 |
| EV / Sales | 5 |
| EV / EBITDA | 18.91 |
| EV / EBIT | 30.95 |
| EV / FCF | 39.63 |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.38.
| Current Ratio | 1.64 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.38 |
| Total Debt / Capitalization | 27.55 |
| Cash Flow / Debt | 0.49 |
| Interest Coverage | 10.17 |
Financial Efficiency
Return on equity (ROE) is 0.15% and return on capital (ROIC) is 10.17%.
| Return on Equity (ROE) | 0.15% |
| Return on Assets (ROA) | 0.08% |
| Return on Capital (ROIC) | 10.17% |
| Revenue Per Employee | 351.83K |
| Profits Per Employee | 50.20K |
| Employee Count | 114.00K |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.74 |
Taxes
| Income Tax | 941.00M |
| Effective Tax Rate | 0.14 |
Stock Price Statistics
The stock price has increased by 0.41% in the last 52 weeks. The beta is 0.72, so Abbott Laboratories's price volatility has been higher than the market average.
| Beta | 0.72 |
| 52-Week Price Change | 0.41% |
| 50-Day Moving Average | 115.4 |
| 200-Day Moving Average | 110.53 |
| Relative Strength Index (RSI) | 42.72 |
| Average Volume (20 Days) | 5.04M |
Income Statement
In the last 12 months, Abbott Laboratories had revenue of 40.11B and earned 5.72B in profits. Earnings per share was 3.3.
| Revenue | 40.11B |
| Gross Profit | 22.13B |
| Operating Income | 6.48B |
| Net Income | 5.72B |
| EBITDA | 10.61B |
| EBIT | 6.48B |
| Earnings Per Share (EPS) | 3.3 |
Balance Sheet
The company has 6.90B in cash and 15.87B in debt, giving a net cash position of -8.98B.
| Cash & Cash Equivalents | 6.90B |
| Total Debt | 15.87B |
| Net Cash | -8.98B |
| Retained Earnings | 37.55B |
| Total Assets | 74.36B |
| Working Capital | 8.90B |
Cash Flow
In the last 12 months, operating cash flow was 7.26B and capital expenditures -2.20B, giving a free cash flow of 5.06B.
| Operating Cash Flow | 7.26B |
| Capital Expenditures | -2.20B |
| Free Cash Flow | 5.06B |
| FCF Per Share | 2.92 |
Margins
Gross margin is 5.52K%, with operating and profit margins of 1.61K% and 1.43K%.
| Gross Margin | 5.52K% |
| Operating Margin | 1.61K% |
| Pretax Margin | 1.66K% |
| Profit Margin | 1.43K% |
| EBITDA Margin | 26.44% |
| EBIT Margin | 16.15% |
| FCF Margin | 12.61% |
Dividends & Yields
ABT pays an annual dividend of $2.36, which amounts to a dividend yield of 2.07%.
| Dividend Per Share | $2.36 |
| Dividend Yield | 2.07% |
| Dividend Growth (YoY) | 15.69% |
| Payout Ratio | 71.73% |
| Earnings Yield | 2.92% |
| FCF Yield | 2.58% |
Analyst Forecast
The average price target for ABT is $129, which is 14.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $129 |
| Price Target Difference | 14.3% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Stock Splits
The last stock split was on Jan 2, 2013. It was a forward split with a ratio of 5000:2399.
| Last Split Date | Jan 2, 2013 |
| Split Type | forward |
| Split Ratio | 5000:2399 |
Scores
| Altman Z-Score | 5.24 |
| Piotroski F-Score | 8 |